Last reviewed 2026-05-13 · How we verify

RZ-629

Rezubio Pharmaceuticals Co., Ltd. · Phase 1 active Small molecule

RZ-629 is a Small molecule drug developed by Rezubio Pharmaceuticals Co., Ltd.. It is currently in Phase 1 development.

At a glance

Generic name	RZ-629
Sponsor	Rezubio Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RZ-629 in Healthy Subjects and T2D (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RZ-629 CI brief — competitive landscape report
RZ-629 updates RSS · CI watch RSS
Rezubio Pharmaceuticals Co., Ltd. portfolio CI

Frequently asked questions about RZ-629

What is RZ-629?

RZ-629 is a Small molecule drug developed by Rezubio Pharmaceuticals Co., Ltd..

Who makes RZ-629?

RZ-629 is developed by Rezubio Pharmaceuticals Co., Ltd. (see full Rezubio Pharmaceuticals Co., Ltd. pipeline at /company/rezubio-pharmaceuticals-co-ltd).

What development phase is RZ-629 in?

RZ-629 is in Phase 1.

Manufacturer: Rezubio Pharmaceuticals Co., Ltd. — full pipeline
Compare: RZ-629 vs similar drugs
Pricing: RZ-629 cost, discount & access